How to buy Akouos stock | $9.18

Akouos Inc is a biotechnology business based in the US. Akouos shares (AKUS) are listed on the NASDAQ and all prices are listed in US Dollars. Akouos employs 69 staff and has a market cap (total outstanding shares value) of 0.00.

Akouos stock price (NASDAQ: AKUS)

Use our graph to track the performance of AKUS stocks over time.

Akouos shares at a glance

• Key figures

Information last updated 2021-10-23.

Latest market close	$9.18
52-week range	$9.39 - $22.82
50-day moving average	$11.53
200-day moving average	$12.46
Wall St. target price	$30.00
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.88

Buy Akouos shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Akouos stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Akouos price performance over time

Historical closes compared with the close of $9.18 from 2021-10-26

1 week (2021-10-21)	-5.94%
1 month (2021-09-28)	-25.97%
3 months (2021-07-28)	-28.06%
6 months (2021-04-28)	-42.48%

1 year (2020-10-27)	-53.87%
2 years (2019-10-24)	N/A
3 years (2018-10-24)	N/A
5 years (2016-10-24)	N/A

Akouos financials

Gross profit TTM	$0
Return on assets TTM	-11.75%
Return on equity TTM	-21.18%
Profit margin	0%
Book value	$8.03
Market capitalisation	$327.6 million

TTM: trailing 12 months

Shorting Akouos shares

There are currently 2.3 million Akouos shares held short by investors – that's known as Akouos's "short interest". This figure is 2.1% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting Akouos shares can be evaluated.

Akouos's "short interest ratio" (SIR)

Akouos's "short interest ratio" (SIR) is the quantity of Akouos shares currently shorted divided by the average quantity of Akouos shares traded daily (recently around 94644.484995945). Akouos's SIR currently stands at 24.66. In other words for every 100,000 Akouos shares traded daily on the market, roughly 24660 shares are currently held short.

However Akouos's short interest can also be evaluated against the total number of Akouos shares, or, against the total number of tradable Akouos shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akouos's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Akouos shares in existence, roughly 70 shares are currently held short) or 0.109% of the tradable shares (for every 100,000 tradable Akouos shares, roughly 109 shares are currently held short).

A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Akouos.

Find out more about how you can short Akouos stock.

Akouos share dividends

We're not expecting Akouos to pay a dividend over the next 12 months.

Akouos overview

Akouos, Inc. , a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc.

Frequently asked questions

What percentage of Akouos is owned by insiders or institutions?
Currently 3.498% of Akouos shares are held by insiders and 95.769% by institutions. How many people work for Akouos?
Latest data suggests 69 work at Akouos. When does the fiscal year end for Akouos?
Akouos's fiscal year ends in December. Where is Akouos based?
Akouos's address is: 645 Summer Street, Boston, MA, United States, 02210 What is Akouos's ISIN number?
Akouos's international securities identification number is: US00973J1016